KANEKA to invest in large-scale production facilities of KANEKA KanCapA™

Kaneka Corporation (Osaka, Japan; President: Mamoru Kadokura) is pleased to announce the construction of large-scale production facilities for the production of KANEKA KanCapA™, our Protein A Chromatography Resin, to meet commercial market demands. The expansion is expected to be complete and operational by early 2015.

Protein A Chromatography Resin is widely used for the purification of monoclonal antibodies due to its high affinity and excellent selectivity for antibodies. KANEKA KanCapA™ was launched for commercial use in 2012, driven by the growing demand for Protein A resin to support the biopharmaceutical market. KANEKA KanCapA™ has already been selected for scale up and clinical development studies by several global pharmaceutical companies, and is actively being evaluated by many others. Our capacity expansion will allow us to meet the larger scale demands from customers as they select KANEKA KanCapA™ for their clinical and marketed products.

With our expanded capacity, we aim to achieve total KANEKA KanCapA™ sales of 10 billion JPY by 2018.